Loading…
Advanced Biomed Inc. is projected to rise to $5.52 by 2027, a +42% move from its current price of $3.88. ADVB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $3.63 | $3.88 | $4.14 | -0.09% |
| May 30 | $3.53 | $3.87 | $4.24 | -0.18% |
| May 31 | $3.46 | $3.87 | $4.33 | -0.27% |
| Jun 1 | $3.40 | $3.87 | $4.40 | -0.36% |
| Jun 2 | $3.34 | $3.86 | $4.46 | -0.45% |
| Jun 3 | $3.29 | $3.86 | $4.52 | -0.54% |
| Jun 4 | $3.25 | $3.86 | $4.58 | -0.63% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.25 | $3.86 | $4.58 | -0.63% |
| Week 2 | $3.01 | $3.83 | $4.88 | -1.26% |
| Week 3 | $2.83 | $3.81 | $5.12 | -1.88% |
| Week 4 | $2.69 | $3.78 | $5.33 | -2.50% |
| Week 5 | $2.56 | $3.76 | $5.51 | -3.12% |
| Week 6 | $2.45 | $3.74 | $5.68 | -3.73% |
| Week 7 | $2.36 | $3.71 | $5.84 | -4.34% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Advanced Biomed Inc. is an investment holding company that engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cell (CTC) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product.
The company also offers microfluidic biochips, such as A+Pre, AC-1000 CTC enrichment, and A+CellScan chips to provide assay products and services to cancer patients. In addition, its immunochromogenic kits include A+CTCE kit to identify epithelial circulating tumor cells and determined by the immunochromogenicity of EpCAM, CK (pan), CD45, and CD14 antibodies; A+CTCM kit to identify mesenchymal circulating tumor cells based on the immunochromogenicity of Vimentin, CD45, and CD14 antibodies; A+EMT to identify epithelial-to-mesenchymal circulating tumor cells determined by the immunochromogenicity of cell-surface Vimentin, and CD45 and CD14 antibodies; and A+CM to identify tumor-associated macrophages based on the immunochromogenicity of PD-L1, CD45, and CD14 antibodies. Further, the company is developing A+LCGuard for early screening of lung cancer.
Additionally, it establishes and operates medical clinics in the People's Republic of China. The company was founded in 2014 and is headquartered in New York, New York.
Advanced Biomed Inc. (ADVB) is a healthcare company focused on microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment as an investment holding company. The current price is $3.95 and the market cap is $6.46M, with a rank of 5278.
The near-term price outlook shows a mixed trajectory, with the forecast indicating a neutral start in 2026 followed by bullish momentum in later years, with averages and ROIs rising across the forecast horizon.
A major floor 57.0% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 85.6% above — a clean break opens room to run.
A major ceiling 114.1% above — clearing it would confirm fresh momentum.
Key ADVB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ADVB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.08 | Sell | $4.07 | Sell |
| MA 10 | $4.30 | Sell | $4.38 | Sell |
| MA 20 | $5.11 | Sell | $4.78 | Sell |
| MA 50 | $5.11 | Sell | $5.11 | Sell |
| MA 100 | $5.26 | Sell | $5.91 | Sell |
| MA 200 | $6.94 | Sell | $10.96 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 36.51 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -99.65 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.17 | Sell |
| ROC (12) | -37.32 | Sell |
| Bollinger %B (20,2) | 0.19 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.59 | Sell |
| Awesome (5,34) | -1.28 | Sell |
| Ultimate (7,14,28) | 24.87 | Buy |
| Momentum (10) | -1.35 | Sell |
| Aroon Osc (25) | -52.00 | Sell |
| Hull MA (9) | 3.83 | Buy |
| ADX (14) | 18.21 | Neutral |
| ATR (14) | 0.29 | Info |
The 30-day technical picture shows bearish sentiment with RSI14 at 40. The price is below the simple moving averages, with SMA50 at $5.18 and SMA200 at $6.97. Key support is at $3.95 and resistance at $7.20. The 30-day range spans from $2.51 to $6.21, and the stock exhibits high annualized volatility at 100%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.72 | $3.88 | $5.42 | 0% | Neutral | |
| $3.84 | $5.52 | $8.60 | +42% | Bullish | |
| $3.83 | $5.92 | $9.87 | +53% | Bullish | |
| $3.10 | $5.09 | $8.95 | +31% | Bullish | |
| $3.20 | $5.58 | $10.24 | +44% | Bullish | |
| $2.59 | $4.76 | $9.08 | +23% | Bullish | |
| $2.19 | $4.25 | $8.38 | +10% | Neutral | |
| $3.19 | $6.50 | $13.20 | +68% | Bullish | |
| $3.27 | $7.02 | $14.64 | +81% | Bullish | |
| $3.21 | $7.14 | $15.25 | +84% | Bullish | |
| $3.95 | $8.77 | $20.18 | +126% | Bullish | |
| $4.96 | $11.03 | $25.36 | +184% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $3.72 | $3.88 | $4.65 | +0.00% |
| June 2026 | $3.28 | $3.97 | $4.98 | +2.22% |
| July 2026 | $2.90 | $3.57 | $4.62 | -9.92% |
| August 2026 | $2.64 | $3.30 | $4.37 | -7.52% |
| September 2026 | $2.81 | $3.55 | $4.78 | +7.60% |
| October 2026 | $2.88 | $3.69 | $5.05 | +3.85% |
| November 2026 | $2.76 | $3.57 | $4.95 | -3.17% |
| December 2026 | $2.95 | $3.86 | $5.42 | +8.01% |
Click any year to see its month-by-month ADVB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Advanced Biomed Inc.'s 2026 outlook centres on $3.88, within a $3.72 to $5.42 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, ADVB could reach as high as $8.60, with a base case around $5.52 and support toward $3.84 — roughly +42% from $3.88. Buyers look set to stay in control over this stretch.
Expect ADVB to range from $3.83 to $9.87 through 2028. The $5.92 average target implies a +53% move from current prices. That is up +7% on the projected 2027 average. Momentum favours further upside here.
The ADVB price prediction for 2029 points to an average of $5.09 (low $3.10, high $8.95) — a potential gain of +31% on today's $3.88. Buyers look set to stay in control over this stretch.
In 2030, ADVB is projected to trade between $3.20 and $10.24, averaging $5.58 — a potential gain of +44% from today's $3.88. That is up +10% on the projected 2029 average. Momentum favours further upside here.
Advanced Biomed Inc.'s 2031 outlook centres on $4.76, within a $2.59 to $9.08 range. That is -15% versus the projected 2030 average. That marks a +23% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, ADVB could reach as high as $8.38, with a base case around $4.25 and support toward $2.19 — roughly +10% from $3.88. Price action looks broadly range-bound.
Expect ADVB to range from $3.19 to $13.20 through 2033. The $6.50 average target implies a +68% move from current prices. That is up +53% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The ADVB price prediction for 2034 points to an average of $7.02 (low $3.27, high $14.64) — a potential gain of +81% on today's $3.88. Momentum favours further upside here.
In 2035, ADVB is projected to trade between $3.21 and $15.25, averaging $7.14 — a potential gain of +84% from today's $3.88. That is up +2% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Advanced Biomed Inc.'s 2040 outlook centres on $8.77, within a $3.95 to $20.18 range. That is up +23% on the projected 2035 average. That marks a +126% change versus current levels. Momentum favours further upside here.
By 2050, ADVB could reach as high as $25.36, with a base case around $11.03 and support toward $4.96 — roughly +184% from $3.88. Buyers look set to stay in control over this stretch.
Investing $1,000 in ADVB today (≈ 257.731959 ADVB) could be worth
$2,842.04
+$1,842.04 (+184%) by 2050 · US Dollar
Based on the average projected ADVB price of $11.03 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ADVBwould be worth at today's price.
$1,000 invested in ADVB on May 27, 2025 (≈ 41.666667 ADVB) would be worth
$161.67
-$838.33 (-83.8%) today · 0.16× · US Dollar
Based on a ADVB entry price of $24 vs. today's $3.88.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.44 | $873.87 | -12.6% |
| 1 month ago | $5.3 | $732.08 | -26.8% |
| 3 months ago | $4.01 | $967.58 | -3.2% |
| 6 months ago | $8.4 | $461.9 | -53.8% |
| 1 year ago | $24 | $161.67 | -83.8% |
| All time (1.2y) ago | $73 | $53.15 | -94.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ADVB forecast.
Our base-case forecast reaches $7.80 around 2040.
Implied market cap at $7.80: $12.75M
Forecasts span to 2050, with the 2026 range showing a near-flat outcome (min $3.72, avg $3.95, max $5.66) and an ROI of 0 with neutral sentiment. In 2027 the avg price is $5.60 with a 41.8% ROI and bullish sentiment, rising further in 2028 to an avg of $5.97 and 51.2% ROI. The 2029 forecast shows an avg of $5.25 and 32.9% ROI.
By 2030 the avg is $5.66 with a 43.3% ROI, and by 2035 the avg reaches $7.30 with an 84.8% ROI. The 2040 forecast projects an avg of $8.84 and a 123.9% ROI, and by 2050 the avg climbs to $11.48 with a 190.5% ROI. Across years, sentiment shifts from neutral in 2026 to bullish in later years, reflecting an upward trajectory with notable upside potential alongside significant volatility.
These figures are estimates and not guarantees.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $5.66 with a 43.3% ROI; the 2030 range is a min of $3.24 and a max of $10.42.
Forecasts show a mix of neutral and bullish sentiment across years, with ROIs including 41.8% in 2027 and 190.5% in 2050; the 2026 projection is neutral with 0% ROI.
Yes. The 2030 max is $10.42, with higher maxima in later years (2033 max $13.49, 2034 max $14.92, 2035 max $15.63, 2040 max $20.34, 2050 max $26.40).
The current price is $3.95 and the market cap is $6.46M.
The near-term picture is bearish with RSI 14 at 40, price trading below SMA50 of $5.18 and SMA200 of $6.97; support is at $3.95 and resistance at $7.20; the 30-day range is $2.51 to $6.21 with volatility around 100%.
Advanced Biomed Inc. Community Discussion
0Share your Advanced Biomed Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.